Code intelligence

FDA-NDA215973 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code FDA-NDA215973.

Critical code risk

Signal breakdown

1 shown · 1 total in platform

Risk: Critical

Critical

100%

High

Routine

Low

New this month

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

FDA Approval: SUNLENCA (LENACAPAVIR SODIUM) — Type 1 - New Molecular Entity

Policy FDA-NDA215973 · Infectious Disease

Critical

Sunlenca (lenacapavir sodium) was approved as a subcutaneous solution for HIV treatment, supporting a Part B billing pathway consistent with its injectable route of administration. As a new molecular

View alert

Audit documentation

Building an audit file that includes FDA-NDA215973?

The Tripwire Audit Pack exports 12 months of single-specialty policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

See audit packs — $349One-time purchase · not a subscription